Analyzing LifeMD (NASDAQ:LFMD) and Castle Biosciences (NASDAQ:CSTL)

LifeMD (NASDAQ:LFMD – Get Free Report) and Castle Biosciences (NASDAQ:CSTL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Volatility & Risk

LifeMD has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

Insider and Institutional Ownership

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 6.1% of Castle Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares LifeMD and Castle Biosciences”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LifeMD $194.05 million 0.55 $14.35 million ($0.05) -43.90
Castle Biosciences $344.23 million 3.03 -$24.16 million ($0.77) -43.88

LifeMD has higher earnings, but lower revenue than Castle Biosciences. LifeMD is trading at a lower price-to-earnings ratio than Castle Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for LifeMD and Castle Biosciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LifeMD 1 1 8 0 2.70
Castle Biosciences 1 1 8 1 2.82

LifeMD currently has a consensus price target of $7.14, indicating a potential upside of 225.41%. Castle Biosciences has a consensus price target of $46.50, indicating a potential upside of 37.61%. Given LifeMD’s higher possible upside, research analysts clearly believe LifeMD is more favorable than Castle Biosciences.

Profitability

This table compares LifeMD and Castle Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LifeMD -0.25% -188.63% -32.24%
Castle Biosciences -6.10% -4.89% -4.06%

Summary

Castle Biosciences beats LifeMD on 7 of the 13 factors compared between the two stocks.

About LifeMD

(Get Free Report)

LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.

Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.